Scientists / Our Scientists

Barzin Nabet

Principal Scientist, Oncology Biomarker Development, Computational Sciences

Postdoc Mentor

"Genentech’s unique culture encourages collaboration between experimental and computational scientists to drive both forward and reverse translation."

Years at Genentech

Publications at Genentech

Awards & Honors

I completed my PhD in at the University of Pennsylvania in 2017 training as an experimental cancer biologist focusing on the mechanisms underlying tumor-stroma interactions. As a postdoctoral fellow at Stanford University, I trained in an environment that allowed me to step away from the bench and focus on translational and computational analyses. This hybrid training enabled me to pursue a career merging experimental and computational approaches to understand cancer biology.

I came to Genentech in 2020 for three main reasons: 1) the collaborative culture that encourages team science, 2) the phenomenal scientists, and 3) real patient impact. Here, I collaborate across departments to understand immune checkpoint inhibitor response and resistance in lung cancers. Our findings translate in the forward direction to inform rational combinations and biomarker selected trials and also in the reverse direction to understand mechanisms of action and identify new targets.

Postdoctoral Mentor

Throughout my career I have benefited from exceptional mentors and hope to continue that tradition. It is incredibly rewarding to learn from trainees and enable them to investigate new areas while they build their own unique skillset and expertise as they transition to independent positions.

Featured Publication

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.

Cancer Cell. 40(3):289-300.

Patil NS*, Nabet BY*, Müller S, Koeppen H, Zou W, Giltnane J, Au-Yeung A, Srivats S, Cheng JH, Takahashi C, de Almeida PE, Chitre AS, Grogan JL, Rangell L, Jayakar S, Peterson M, Hsia AW, O’Gorman WE, Ballinger M, Banchereau R, Shames DS.

*Co-first and corresponding authors

View Abstract

My research focus is primarily on non-small cell lung cancer and small cell lung cancer. While immune checkpoint inhibitors have transformed care for many lung cancer patients much is left to be understood about response and resistance. We utilize advanced analytics of multi-omic profiles of patient tumors in the context of large randomized clinical trials to understand the molecular features and tumor subtypes that drive response or resistance to immune checkpoint inhibition.

Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade

Cancer Cell, ISSN: 18783686 15356108

Habib Hamidi; Yasin Senbabaoglu; Niha Beig; Juliette Roels; Cyrus Manuel; Xiangnan Guan; Koeppen; Zoe June Assaf; Barzin Y. Nabet; Adrian Waddell; Kobe Yuen; Sophia L. Maund; Ethan S. Sokol; Jennifer M. Giltnane; Amber Schedlbauer; Eloisa Fuentes; James D. Cowan; Edward E. Kadel III; Viraj Degaonkar; Alexander Andreev-Drakhlin; Patrick Williams; Corey A. Carter; Suyasha Gupta; Elizabeth E. Steinberg; Yohann Loriot; Joaquim Bellmunt; Petros Grivas; Jonathan E. Rosenberg; Michiel S Van Der Heijden; Matthew D. Galsky; Thomas Powles; Sanjeev Mariathasan; Romain Banchereau

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Barzin Nabet

Principal Scientist, Oncology Biomarker Development, Computational Sciences

Featured Publication

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.